We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance Gives Recommendations on Reconstituting Blood Products
FDA Guidance Gives Recommendations on Reconstituting Blood Products
February 15, 2007
The U.S. Food and Drug Administration (FDA) issued a draft guidance with recommendations on how blood product manufacturers can apply for licenses to use placental or umbilical cord blood treatments for hematological malignancies.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor